Lineage Cell Therapeutics FY2028 EPS Lowered by B. Riley

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Stock analysts at B. Riley decreased their FY2028 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, August 15th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.15 for the year, down from their prior forecast of $0.20. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics’ FY2029 earnings at $0.11 EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. D. Boral Capital restated a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a research report on Thursday, August 14th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $4.25.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN:LCTX opened at $1.24 on Monday. The company has a market cap of $283.17 million, a P/E ratio of -6.89 and a beta of 1.66. Lineage Cell Therapeutics has a one year low of $0.3651 and a one year high of $1.31. The business’s 50-day simple moving average is $1.00 and its 200 day simple moving average is $0.69.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several large investors have recently added to or reduced their stakes in LCTX. Hudson Bay Capital Management LP acquired a new position in shares of Lineage Cell Therapeutics in the 2nd quarter worth approximately $44,000. Brevan Howard Capital Management LP bought a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $281,000. Raymond James Financial Inc. grew its position in Lineage Cell Therapeutics by 136.2% during the 2nd quarter. Raymond James Financial Inc. now owns 69,380 shares of the company’s stock worth $63,000 after acquiring an additional 40,009 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $35,000. Finally, WINTON GROUP Ltd bought a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.